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ABSTRACT 
Background: Weikangfu granule compound (WKC) is a drug preparation 
based on a clinical prescription drug, Weikangfu-tang, which has been found to 
have therapeutic effects on gastric cancer. WKC comprises 7 components, in- 
cluding polysaccharides, saponin, flavonoids, and essential oil. 
Objective: The purpose of this study was to assess the antitumor and im- 
munomodulatory effects of WKC in a tumor-bearing rodent model. 
Methods: Male and female Kuming mice weighing -20 g were subcutaneous- 
ly implanted with sarcoma 180 ($180) tumor cells and randomly assigned to 1 of 
5 treatment groups: oral WKC 175, 350, or 525 mg/kg • d, isotonic saline (nega- 
tive control), or intraperitoneal cyclophosphamide 25 mg/kg • d (positive con- 
troD. All treatments were administered daily for 10 days. After euthanization  
day 11, the mice, tumors, and spleens were weighed. Lymphocyte proliferation 
and cytotoxic T lymphocyte (CTL) activity were determined using the 3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cellular viability assay 
method. Macrophage phagocytosis was identified using a yeast est. 
Results: Fifty mice were included in the study (10 mice were assigned to 
each group). The tumors of the mice administered WKC 175, 350, and 525 mg/ 
kg • d were significantly regressed, as determined using MICs, compared with 
those in the negative-control group (P < 0.05, P < 0.01, and P < 0.01, respec- 
tively), and the inhibitory rates were 30.43%, 46.72%, and 54.35%, respectively. 
Compared with those in the negative-control group, CTL activities and lympho- 
cyte proliferations in the presence of concanavalin A were significantly greater 
in the WKC-treated groups at all doses (CTL activities: P < 0.05, P < 0.01, and 
P < 0.01, respectively; lymphocyte proliferations: P < 0.05, P < 0.01, and P < 0.01, 
respectively). In the groups receiving WKC 175, 350, and 525 mg/kg • d, the 
phagocytic rates were 1.5- to 2.0-fold those in the negative-control group (P < 
0.05, P< 0.01, and P< 0.01, respectively). In the groups receiving WKC 175,350, 
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and 525 mg/kg • d, the phagocytic indexes were 3.7- to 5.0-fold those in the 
negative-control group (all, P < 0.01). In contrast, lymphocyte proliferation 
in the positive-control group was significantly less compared with that in the 
negative-control group (P < 0.01), but no significant differences were found in 
CTL activities or macrophage phagocytosis between these 2 groups. 
Conclusion: The results of this study in a rodent model suggest hat WKC 
exhibited antitumor and immunomodulatory activities in S180-bearing mice, 
and that WKC improved nonspecific and specific immune functions in mice, 
such as lymphocyte proliferation, CTL activity, and macrophage phagocytosis. 
(Curt Ther Res Clin Exp. 2006;67:138-150) Copyright © 2006 Excerpta Medica, Inc. 
Key words: Weikangfu granule compound, $180 tumor, antitumor activity, 
immunomodulation activity. 
INTRODUCTION 
Chinese herbal medicines (CHMs) have been widely used in many countries for 
thousands of years, and recently have been used clinically to treat cancer or as 
adjuvant herapy. 1 Some CHMs, including prescription CHMs, are thought o 
have marked antitumor and antimetastatic effects, with a low risk for toxicity in 
normal tissue, and immunomodulatory properties. 2-5 In recent years, the medi- 
cal potential of CHMs has drawn increasing attention to scientists. Some CHMs 
and their bioactive components have been reported to have chemotherapeutic 
effects. 64 For example, in a study of the anticancer effects of 3-day treatment 
with the CHM Scutellaria baicalensis in human cell lines of head and neck squa- 
mous cell carcinoma, Zhang et al 6 found that the drug was associated with anti- 
cancer activity in vitro and in vivo (dose- and time-dependent growth inhibition 
[median inhibitory concentration i  both cell lines: 150 1Jg/mL], dose-dependent 
significant suppression ofproliferation cell nuclear antigen expression at 1501Jg/mL 
in both cell lines [both, P < 0.05], and significant inhibition of cyclooxygenase-2 
expression in both cell lines at 1.5-150 1Jg [both, P _ 0.05]). In a study of the 
chemotherapeutic effects of 2- to 3-day treatment with the CHM Euphorbia fis- 
cheriana in a human prostate cancer cell line, Liu et al 7 found that the drug was 
associated with inhibitory effects (regulation of proliferation, neuroendocrine 
differentiation, and apoptosis) in vitro. In a study of the anticancer effects of 0.5- 
to 2.0-hour treatment with eugenol, a component of the essential oil isolated 
from Eugenia caryophyllata, on human promyelocytic leukemia cells, Yoo et al 8 
found that the drug was associated with apoptosis (cytotoxicity, increased DNA 
fragmentation, generation of reactive oxygen species, loss of mitochondrial 
transmembrane potential). 
Weikangfu granule compound (WKC) is a drug preparation partly based on a 
clinical prescription medication, Weikangfu-tang. Weikangfu-tang consists of 4 
herbs: rhizome of Curcuma wenyujm, root of Astralagus membranaceus, root of 
Glycyrrhiza inflata, and sclerotium of Poria cocos. Previous tudies 9-14 in humans 
have reported that Weikangfu-tang was associated with therapeutic effects on 
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gastric cancer, with significantly effective and total effective rates of 52.46% and 
90.16%, respectively (significantly effective rate, P < 0.01; total effective rate, 
P < 0.05 and P < 0.01). WKC has 7 components: 
• Essential oil of Curcuma wenyujin 
• Polysaccharides ofAstralagus membranaceus (Fisch.) Bge. var mongholicus 
• Saponins of Astralagus membranaceus (Fisch.) Bge. var mongholicus 
• Polysaccharides of Glycyrrhiza inflata Bat. 
• Glycyrrhizic acid of Glycyrrhiza inflata Bat. 
• Flavonoids of Glycyrrhiza mflata Bat. 
• Poriatin of Poria cocos (Schw.) Wolf 
In this study, the purpose was to assess the antitumor and immunomodula- 
tory activities of WKC in a tumor-bearing rodent model. To do so, the prolifera- 
tive responses of spleen lymphocytes with or without T cell mitogen, the activity 
of cytotoxic T lymphocytes (CTLs), and phagocytosis of peritoneal macro- 
phages were examined. 
MATERIALS AND METHODS 
Preparation of Weikangfu Granule Compound 
The components of WKC were obtained from Nantong Sihai Plant Extract 
Co., Ltd. (Nantong, People's Republic of China [PRC]). The purity of each 
component was >70%. The components were mixed according to a certain 
proportion. 
Animals and Cells 
Male and female Kuming mice aged -4 weeks and weighing -20 g were pur- 
chased from the Animal Research Center, Center for Disease Control and 
Prevention of Jiangsu Province, PRC. The mice were randomly assigned to 1 of 
5 groups: oral WKC 175, 350, or 525 mg/kg • d, isotonic saline (negative control), 
or intraperitoneal cyclophosphamide (provided by Ruiheng Co., Ltd., Suzhou, 
PRC) 25 mg/kg • d (positive control). The mice were housed in plastic cages with 
wood-chip bedding in an animal room with a 12-hour light-dark cycle at room 
temperature (25°C [2°C]), and allowed free access to a standard laboratory diet 
and water. Animal handling was conducted in accordance with the regulation 
for the use of laboratory animals, and the study protocol was approved by the 
ethics committee at the university. 
Mouse sarcoma 180 cells ($180) and colon 26 carcinoma cells (C26) were pro- 
vided by the Shanghai Institute of Cell Biology, Chinese Academy of Science, 
Shanghai, PRC. C26 cells were cultured in RPMI 1640 medium (Gibco BRL, Grand 
Island, New York) supplemented with 10% fetal bovine serum (FBS) (Shanghai 
Institute of Cell Biology) at 37°C in a humidified 5% CO 2 incubator. $180 cells 
were maintained in the peritoneal cavities of the mice. 
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Assay of Antitumor Activity and Spleen Weight 
Six-day-old $180 ascites tumor cells (-2 x 106 cells; 0.2 mL)were sub- 
cutaneously implanted into the right hind groin of the mice. One day after inocu- 
lation, the study drugs were administered. All treatments were administered for 
10 days. On day 11, the mice were euthanized, and the mice, tumors, and spleens 
were weighed. The inhibitory rate was calculated as follows15: 
Inhibitory rate (%) = [(A- B)/A] x 100 
where A was the mean tumor weight of the negative-control group, and B was 
that of the WKC-treated or positive-control group. Relative spleen weight was 
measured as the ratio of the spleen weight (in milligrams) to body weight (in 
grams). 
Histopathology and Morphologic Observations 
The histopathology of $180 tumor was tested as described by Yang et al. 16 
After euthanization, portions of tumor from each group were randomly select- 
ed and coded. Each tumor was fixed in 10% formalin, dehydrated by graded 
ethanol, embedded with paraffin, cut into small pieces, fixed in Heidenhain's 
Suea Fluid (HgC12, 4.5 g; NaC1, 0.5 g; distilled water, 80.0 mL; formalin, 20.0 mL; 
acetic acid, 4.0 mL; trichloroacetic acid, 2.0 mL), stained with hematoxylin and 
eosin, and examined and photographed under an optical microscope (Olympus 
Corporation, Tokyo, Japan; magnification, 100 x and 400 x). Personnel involved 
in these procedures were blinded to treatment assignment. 
Preparation of Mouse Splenocytes 
Splenocytes were prepared as described by Lee et al. 2 Spleens were asepti- 
cally extirpated from the mice and placed in phosphate-buffered saline (PBS) 
(0.01 M; pH 7.2). Splenocytes were obtained in PBS by forcing spleen fragments 
through stainless mesh, treated with a hypotonic solution to lyse erythrocytes, 
and washed twice with PBS. The viability of the splenocytes was >95%, as 
assessed by the trypan blue dye exclusion method described by Cheng. 17 The 
cells were resuspended in RPMI 1640 medium supplemented with 10% FBS. The 
concentration of splenocytes was adjusted to 2 x 106 cells/mL. 
Assessment of Lymphocyte Proliferation 
To investigate the effect of WKC on the cellular immune response, we eval- 
uated spleen lymphocyte proliferation and CTL activity in S180-bearing mice. 
The proliferation of spleen lymphocytes was determined using the 3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium br mide (MTT) cellular viability 
assay method (Sigma Diagnostics, St. Louis, Missouri). 17,18 Two hundred micro- 
liters of splenocyte suspension (2 × 106 cells/mL) was placed into 96-well mi- 
croplates and cultured with or without concanavalin A (ConA) 5 1Jg/mL (Sigma 
Diagnostics) at 37°C in a humidified 5% CO 2 incubator for 68 hours. Ten micro- 
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liters of MTT solution (5 mg/mL) was added to each well and incubated for an 
addit ional  4 hours  for MTT cel lular viabi l i ty assay. All determinat ions  were 
conducted in triplicate. Proliferation activity was expressed as the absorbance  
at 570 nm. 19 
Assays of Cytotoxic T Lymphocytes 
Splenocytes  from each mouse  were prepared  as descr ibed prev ious ly  and 
used as effector cells. To determine CTL act iv ity (percentage of target cells 
killed), MTT assay  was conducted  accord ing to previous reports .  2°,21 C26 
cells were used as the target cells. The cells were plated into 96-well 
microp lates  at a densi ty  of 5 × 103 cells/well in RPMI 1640 medium, and cul- 
tured for 24 hours  at 37°C in a humidif ied 5% CO 2 incubator.  Then spleno- 
cytes were added at 5 × 105 cells/well. The cell ratio of ef fector-to-target was 
100:1. After 68-hour incubation,  10 1JL MTT solut ion was added to each well 
and cultured for an addit ional 4 hours.  RPMI 1640 medium and sp lenocytes  
were removed,  and C26 cells were washed twice with PBS. One hundred fifty 
microl i ters of d imethyl  sulfoxide was added to each well. The absorbance  
was detected at 570 nm using an enzyme-l inked immunosorbent  assay  plate 
reader  (EL × 800, BioTek, Winooski, Vermont).  All determinat ions  were con- 
ducted in tr ipl icate. To determine the CTL activity, the following equat ion 
was used: 
CTL activity (%) = (T - M)/T × 100 
where Twas  the mean of the absorbance  of target cells incubated alone, and M 
was the mean of the absorbance of target cells incubated with effector cells. 
Assay of Macrophage Phagocytosis 
Yeast was suspended in isotonic saline, heated for 10 minutes at 100°C to 
remove the impurity, and dried at 70°C. Then the dried yeast (1 g) was sus- 
pended in 100 mL of isotonic saline before the experiment. 
After WKC administration for 10 days, the mice were intraperitoneally 
injected with 3 mL sterile isotonic saline before euthanization on day 11. Then 
ascites (1 mL) was drawn out 2 minutes later, seeded on a microscope slide, and 
incubated for 50 minutes at 37°C to allow macrophage adhesion. Nonadherent 
cells were washed away with isotonic saline. The remaining adherent cells were 
used as the monolayer of peritoneal macrophages. The monolayer of peritoneal 
macrophages was co-incubated with yeast suspension for 40 minutes at 37°C. 
The macrophages were rinsed with isotonic saline to remove non-cell-ingested 
yeast, fixed with glutaraldehyde fixative, and stained with 1% methylene blue 
solution (Sigma Diagnostics). For each microscope slide, -100 macrophages 
were examined with the Olympus microscope using a 400 × objective lens. All 
determinations were conducted in triplicate. The phagocytic rate was calcu- 
lated as follows22: 
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No. of macrophages containing yeast cells 
Phagocytic rate = × 100 
Total macrophages counted 
The phagocytic index was calculated as follows23: 
Phagocytic index = 
No. of yeast cells inside macrophages 
No. of macrophages phagocytosing 
× 100 
Statistical Analysis 
The data obtained were analyzed statistically using the analysis of variance 
method for repeated measurements.  Significance of any differences between 
WKC-treated groups and the negative-control group was assessed using the 
Student test. P < 0.05 was considered statistically significant. Statistical analy- 
sis was performed using SPSS version 9.0 (SPSS Inc., Chicago, Illinois). All data 
were expressed as mean (SD). 
RESULTS 
Fifty Kuming mice were studied (mean [SD] weight, 20.0 [2.0] g; 10 mice per 
study group). 
Tumor and Spleen Weight 
The effects of WKC on S180-bearing mice are shown in Table I. WKC 175,350, 
and 525 mg/kg • d were found to be associated with significant growth inhibition 
of S180 tumor compared with the negative-control group (P < 0.05, P < 0.01, and 
P < 0.01, respectively). WKC 175, 350, and 525 mg/kg • d were found to be asso- 
Table I. Effects of Weikangfu granule compound (WKC) on tumor and spleen in S180- 
bearing mice (n = 10 mice per study group). 
Increase in Relative Tumor Inhibitory 
Body Weight, Spleen Weight, Weight, Rate, 
Study Group Mean (SD), g Mean (SD), mg/g Mean (SD), g % 
Negative control* 6.0 (1.8) 5.43 (0.70) 0.92 (0.35) - 
Positive control t -0.2 (2.1)* 3.16 (0.39) § 0.34 (0.26) § 63.04 
WKC 
175 mg/kg • d 5.9 (2.9) 6.19 (0.41) 0.64 (0.34)* 30.43 
350 mg/kg • d 6.6 (2.5) 6.34 (0.73) § 0.49 (0.22) § 46.72 
525 mg/kg • d 6.2 (1.4) 6.21 (0.68)* 0.42 (0.40) § 54.35 
*This group received physiologic saline. 
tThis group received cyclophosphamide 25 mg/kg • d. 
*P < 0.05 versus negative control (Student test). 
§P < 0.01 versus negative control (Student test). 
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ciated with significant inhibition of S180 tumor growth in a dose-dependent 
manner compared with the negative-control group, with inhibitory rates of 
30.43%, 46.72%, and 54.35%, respectively. In addition, relative spleen weights in 
the groups treated with WKC 350 and 525 mg/kg • d were significantly greater 
compared with those in the negative-control group (P < 0.01 and P < 0.05, 
respectively). No significant differences in body weight were found between the 
groups treated with WKC and the negative-control group. On the other hand, 
cyclophosphamide was associated with a significant decrease in body and 
spleen weights (P < 0.05 and P < 0.01, respectively), although it was also asso- 
ciated with significant growth inhibition compared with the negative-control 
group (63.04%; P < 0.01). 
Histopathologic and Morphologic Assessments 
On histopathology of S180 tumor from the WKC-treated groups (Figures 1 and 
2), the border between tumor and fatty tissue was distinct, and the tumor cells 
had nucleus pycnosis and necrosis areas in different degrees. In contrast, tumor 
in the negative-control group invaded into fatty tissue and grew vigorously. 
Cellular Immunity 
As shown in Figure 3, treatment with WKC resulted in a statistically significant 
increase in lymphocyte proliferation with or without T cell mitogenic stimuli, and 
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Figure 1. Invasion of $180 tumor into fatty tissue after 10-day oral administration of 
Weikangfu granule compound (WKC). (A) Negative control; (B) WKC 175, 
(C) 350, (D) 525 mg/kg • d. (Hematoxylin and eosin; magnification, 100 ×.) 
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Figure 2. Mean morphologic appearance after 10-day oral administration of Wei- 
kangfu granule compound (WKC). (A) Negative control; (B) WKC 175, 
(C) 350, (D) 525 mg/kg • d. (Hematoxylin and eosin; magnification, 400 ×.) 
the levels of lymphocyte proliferation in the presence of ConA were significantly 
greater at 175, 350, and 525 mg/kg • d compared with that in the negative-control 
group (P < 0.05, P < 0.01, and P < 0.01, respectively). However, lymphocyte  prolifer- 
ation in the positive-control group was significantly decreased compared with nega- 
tive controls (P < 0.01). Furthermore, CTL activities were significantly enhanced in 
S180-bearing mice with WKC at the doses of 175, 350, and 525 mg/kg • d (P< 0.05, 
P < 0.01, and P < 0.01, respectively), in a dose-dependent  manner  (F ig . re  4). 
Macrophage Phagocytos i s  
As summar ized  in Table  II, the phagocyt ic  rates and indexes of the WKC- 
t reated groups were 1.5- to 2-fold and 3.7- to 5-fold those  of the negat ive-contro l  
group, respectively. Compared  with those  in the negat ive-contro l  group, the 
phagocyt i c  rates and indexes were signif icantly higher in the groups t reated 
with WKC 175, 350, and 525 mg/kg • d (for phagocyt ic  rates: P < 0.05, P < 0.01, 
and P < 0.01, respect ively;  for phagocyt i c  indexes: all, P < 0.01). 
DISCUSSION 
The resul ts  of this s tudy  suggest  that  WKC cou ld  act ivate  per i tonea l  
macrophage and enhance  per i toneal  macrophage phagocytos i s  in S180-bearing 
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Figure 3. Spleen lymphocyte proliferation in S180-bearing mice after oral administra- 
tion of Weikangfu granule compound (WKC). Spleen lymphocytes were 
obtained and cultured with or without concanavalin A (ConA). Proliferation 
activity was expressed as the absorbance at 570 nm. *P < 0.01 versus negative- 
control group (Student t test); tp < 0.05 versus negative-control group 
(Student t test). ~This group received isotonic saline. §This group received 
cyclophosphamide 25 mg/kg • d. 
20 -  
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Figure 4. Mean cytotoxic T lymphocyte (CTL) activity in S180-bearing mice after oral 
administration of Weikangfu granule compound (WKC). Spleen lympho- 
cytes were obtained and cultured with C26 cells for 72 hours. CTL activity 
was expressed as (T -  M)/T x 100, where Tis the mean of the absorbance 
of target cells incubated alone, and M is that of target cells incubated with 
effector cells. *P < 0.05 versus negative-control group (Student t test); tp < 
0.01 versus negative-control group (Student t test). ~This group received 
isotonic saline. §This group received cyclophosphamide 25 mg/kg • d. 
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Table II. Effects of Weikangfu granule compound (WKC) on macro- 
phage phagocytosis in S180-bearing mice (n = 10 mice per 
study group). 
Phagocytic Rate, Phagocytic Index, 
Study Group Mean (SD), % Mean (SD) 
Negative control* 30.1 2 (7.28) 0.95 (0.22) 
Positive control t 1 7.22 (6.83) 0.65 (0.18) 
WKC 
175 mg/kg • d 45.80 (4.74)~ 3.76 (0.86)§ 
350 mg/kg • d 63.02 (8.05) § 5.08 (1.02) § 
525 mg/kg • d 58.79 (7.96)§ 4.59 (1.35)§ 
*This group received isotonic saline. 
tThis group received cyclophosphamide 25 mg/kg • d. 
~P < 0.05 versus negative control (Student t test). 
§P < 0.01 versus negative control (Student t test). 
mice. The relationship between the occurrence, growth, and decline of tumor 
and immune states is the essential problem of tumor immunology. The discov- 
ery of new antitumor drugs that can potentiate immune function has become 
an important goal of research in immunopharmacology andimmunotherapy. 19 
In this study, a tumor-bearing animal model was used to research the antitumor 
and immunomodulatory activities of WKC. 
The results of the present study suggest hat WKC significantly inhibited 
$180 tumor formation in a dose-dependent manner, without causing a signifi- 
cant decrease in body or spleen weight in mice. Results on histopathology sug- 
gest that WKC prevented the tumor invasion into fatty tissue. With 10-day WKC 
treatment, he relative spleen weights in S180-bearing mice were significantly 
greater compared with those of the 2 control groups. The relative spleen weight 
is an important indicator of nonspecific immunity. 24In a study of the effects of 
10-day treatment with 3 doses of polysaccharide L-II on cellular immune 
response in S180-bearing mice, Zheng et a124 found that use of immunopotentia- 
tors might increase spleen and thymus weights, and that use of immunosup- 
pressive agents might decrease spleen and/or thymus weight and/or lead to a 
decline in immune function. Based on those results, WKC might have immune 
potentiator properties. 
Protective immunity against umor comprises cellular and humoral immu- 
nity. Immune responses, especially cellular immunity, play an important role in 
the elimination of locally growing and circulating tumor cells and thus result in 
the inhibition of growth and metastasis of tumors. 25 In the present study, cell- 
mediated immune defense seemed to be mediated specifically by T cells, 
including cytotoxic T cells. T cells can kill tumor cells and produce many lym- 
phocytic factors, including macrophage mobile factor, lymphotoxin, transfer 
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factor, and interferon, which can enhance macrophage phagocytosis and the 
capacity of killing target cells. 26 The results of the present study suggest hat 
WKC at all doses significantly enhanced spleen lymphocyte proliferation and 
CTL activity with or without stimulation by T cell mitogen (ConA). 
Macrophages have diverse functions, including phagocytosis, tumor cytotox- 
icity, cytokine secretion, and antigen presentation. They represent a defense 
line against pathogens and tumor cells, recognizing and destroying them. 27,28 
The enhancement of phagocytic function is applicable for therapy of cancer, 
because phagocytes act as regulator and effector cells in the immune system, 
and phagocytosis represents the indispensable step of the immunologic 
defense system. 29 Therefore, stimulation of macrophages might be a major 
target for therapeutic application. 3°,31 This study also found that oral adminis- 
tration of WKC was associated with significant improvement in macrophage 
phagocytic function in S180-bearing mice. 
Study Limitations 
The present study had some limitations, including the lack of a pharmacody- 
namic test of each independent component in the formulation. In the treatment 
of S180-bearing mice, each effective component might exert a different function. 
Some might induce main effects, whereas others might not. It is necessary to 
assess the pharmacodynamic function of each component in the medication in 
future research. In addition, although WKC is composed of effective compo- 
nents extracted from natural drugs, the adverse ffects of WKC (eg, hepatotox- 
icity and renal toxicity) remain to be studied. 
CONCLUSION 
The results of this study in a rodent model suggest hat WKC exhibited anti- 
tumor and immunomodulatory activities in S180-bearing mice, and that WKC 
improved nonspecific and specific immune functions in mice, such as lymphocyte 
proliferation, CTL activity, and macrophage phagocytosis. 
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